Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial.

G Bisogno, M Jenney, C Bergeron, Melcón S Gallego, A Ferrari, O Oberlin, M Carli, M Stevens, A Kelsey, Paoli A De, MN Gaze, H Martelli, C Devalck, European paediatric Soft tissue sarcoma Study Group

Research output: Contribution to journalArticleResearchpeer-review

89 Citations (Scopus)
Original languageUndefined/Unknown
JournalThe Lancet. Oncology
Publication statusPublished - Jun 2018

Cite this